HelixMind

Predicting microbial evolution and antibiotic resistance with AI — empowering scientists to design smarter experiments and stay ahead of AMR.

[HelixMind @HelixMind_]

Most pathogenicity tools just give a score.
We plugged AlphaMissense straight into Mutation Simulator real model output, not a proxy. Biggest edge: disordered regions, where BLOSUM-style scores often guess.

Early days. Tracking where it matches published data and where it doesnt

[J.J. @Codaracodes]

A year ago i didn’t know shit in Bio and now I’m tackling genetic analysis, drug discovery, mutations of organisms over generations, now working on 9TB+ of Genetic Data

Pretty Awesome if you ask me!

[J.J. @Codaracodes]

T2T Genome Assembly — 6.93TB dataset, in progress. It’s amazing so let’s see where we go with this

@undiagnosed_1
@oxMichelangelo
@Research2People
@openlabsbio
@BioProtocol

https://t.co/DKlbMValqM

[OpenLabs @openlabsbio]

New on OpenLabs: meet HelixMind

HelixMind aims to help researchers test ideas computationally and catch potential failures before experiments reach the lab bench.

Its first discussion explores a self-hosted pipeline for detecting antimicrobial resistance, combining ResFinder with additional sequence analysis to investigate whether it can reduce false positives while keeping genomic data local.

Explore the approach and join the discussion ↓

[HelixMind @HelixMind_]

@Flextor97 They can flag known mechanisms and some early risk signals, but for completely new compounds the models still need wet-lab data to stay reliable. Hybrid approach is winning right now: AI narrows the field, experiments confirm (and improve the models).

[HelixMind @HelixMind_]

@MedLearnHub Generative models designing antibiotics and forecasting immune responses marks a clear shift. The science is moving from analysis into active design much faster than most clinical workflows.

[MedLearn Hub @MedLearnHub]

We’re sitting on a quiet revolution in clinical medicine, and it isn't happening in a wet lab.

Generative AI is no longer just predicting protein folds - it’s actively designing new antibiotics from scratch and predicting individual immune responses to vaccines.

Here’s what’s changing, from a doctor to my fellow medicos and general public.🧵👇

[HelixMind @HelixMind_]

@luispedrocoelho @agraybee This is a real communication problem in the field. Many genuine advances in microbial genomics and AI already sound exaggerated until you look at the actual data.

[HelixMind @HelixMind_]

@FrontInfectDis A structured overview of A. baumannii vaccine research is useful. Mapping the landscape helps identify where new approaches (including AI-guided ones) can add the most value.

[HelixMind @HelixMind_]

@FrontInfectDis 12-year within-patient data on how long non-susceptibility persists is valuable. These kinds of longitudinal studies help ground resistance predictions in real clinical dynamics.

[HelixMind @HelixMind_]

@PrettyBlogPink AI-designed antibiotics showing efficacy in mice against drug-resistant infections is meaningful progress. Moving from computational hits to in-vivo results is still the hardest step.

[HelixMind @HelixMind_]

@ChronosIntelX Scanning extinct animals and ancient plants for antibiotic candidates is a clever expansion of the search space. 37,000 hits is a lot to filter, but the approach shows how much chemical diversity is still untapped.

[HelixMind @HelixMind_]

@SynBioBeta DNA storage keeps looking more realistic. Energy efficiency is the big long-term advantage if the read/write costs come down.

[HelixMind @HelixMind_]

@NatureBiotech @StJudeResearch AI optimising large-scale cloud computing for drug discovery is practical progress. Compute efficiency matters when screening gets this big.

[HelixMind @HelixMind_]

@DivaBiotech The confidence is real, but healthcare GTM has hard regulatory and compliance constraints that dinner meetings don’t solve. Experience shows quickly.

[HelixMind @HelixMind_]

@MicroResRep Unsupervised clustering of IBD microbiomes into distinct bacterial subtypes is useful. Better patient stratification could improve both research and treatment design.

[HelixMind @HelixMind_]

@DavidUllrich202 Another example of AI screening millions of compounds and surfacing a new antibiotic class active against resistant bacteria. The discovery rate is picking up.

[HelixMind @HelixMind_]

@MedLearnHub AI designing peptides that scramble bacterial bioelectric signals is a different angle from classic cell-wall targets. Interesting shift in approach.

[HelixMind @HelixMind_]

@FrontInfectDis Timely editorial. AI is moving from simple resistance prediction into deeper pathogenesis and drug-resistance mechanisms. The field needs more of this.